Document is current
Any future updates will be listed below
-
Authors
Patel, Akshay J.
Tan, Ti-Myen
Richter, Alex G.
Naidu, Babu
Blackburn, Jonathan M.
Middleton, Gary W. http://orcid.org/0000-0001-5695-3474
-
Funding
Funding for this research was provided by:
Cancer Research UK
- License Information
-
More Information
Article History
Received: 19 June 2021
Revised: 12 September 2021
Accepted: 30 September 2021
First Online: 2 November 2021
Ethics approval and consent to participate
: All participants provided informed consent to participate in future translational studies when they were initially recruited, previously approved by the West Midlands—Solihull Research Ethics Committee (Cancer of the Lung Biomarkers (CLUB): REC reference: 04/Q2704/34). The study had National Cancer Research Network (NCRN) approval and was an NCRN portfolio study. The study was performed in full accordance with the Declaration of Helsinki.
: No individual patient-identifiable data was used, all were pseudonymised and full consent was gained as part of the recruitment process.
: JMB is a Director of Sengenics Corporation, who commercialise the Immunome protein array.
